R&D | October 29, 2025
Orion secures license to Abzena’s next-generation cancer antibody
The antibody was designed and developed at Abzena’s Cambridge, UK,
The antibody was designed and developed at Abzena’s Cambridge, UK,
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
_256_384.jpg)
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
This partnership marks a significant step in strengthening Healthium’s position in the cardiac care segment
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
FineCross M3 empowers physicians to perform safer PCI procedures, helping improve outcomes in patients with challenging coronary anatomies
States exhorted to ensure rational use of cough syrups, particularly among children, as most coughs are self-limiting and do not require pharmacological treatment
Subscribe To Our Newsletter & Stay Updated
